Irritable Bowel Syndrome (IBS) Treatment Market Trends, Business Growth and Major Driving Factors 2028
The irritable bowel syndrome (IBS) treatment market was valued at US$ 2,153.89 million in 2020 and is projected to reach US$ 4,600.30 million by 2028; it is expected to grow at a CAGR of 10.1% from 2021 to 2028.
According to our latest study on “Irritable Bowel Syndrome (IBS) Treatment Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Product, and Distribution Channel,” the market was valued at US$ 2,153.89 million in 2020 and is projected to reach US$ 4,600.30 million by 2028; it is expected to grow at a CAGR of 10.1% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.
Get Sample PDF Brochure of Irritable Bowel Syndrome (IBS) Treatment Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://www.theinsightpartners.com/sample/TIPRE00006814/
Based on type, the irritable bowel syndrome (IBS) treatment market is segmented into mixed IBS (IBS-M), IBS with diarrhea (IBS-D), and IBS with constipation (IBS-C). The mixed IBS (IBS-M) segment held the largest share of the market in 2020. Also, the same segment is expected to register the highest CAGR during 2021–2028. In the coming years, the rising prevalence of IBS among women and men is anticipated to propel the demand for the medicines that can treat combined symptoms of constipation and diarrhea. According to updated Rome IV criteria, the reverse condition of IBS-M is described as a model of hard or irregular stools in more than 25% of bowel movements. The prevalence is higher in the geriatric population. Therefore, the demand for medicines to treat mixed IBS is likely to grow significantly during the forecast period,
The growth of the irritable bowel syndrome (IBS) treatment market is primarily attributed to the key driving factors such as increasing IBS diseases prevalence and rising research & development activities. However, the limited number of product availability and treatment inefficiency hinder the market growth. Ironwood Pharmaceuticals, Inc.; AbbVie.; Sebela Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Alfasigma S.p.A.; Astellas Pharma Inc.; AstraZeneca; Synthetic Biologics, Inc.; Bausch + Lomb Incorporated; and Lannett Company Inc are among the leading companies operating in the market.
Our report on Irritable Bowel Syndrome (IBS) Treatment Market cover following key parameters:
Comprehensive market analysis at global, regional and country level
Detailed PEST (Political, Economic, Social and Technological) factors impacting the market across key geographic regions such as North America, Europe, Asia Pacific, Middle East & Africa, and South America
Market dynamics (drivers, restraints, opportunities, and future trends) and impact analysis of drivers and restraints at short-term, mid-term and long-term
In-depth market segmentation and deep dive regional and country level analysis of 18+ countries across 5 key regions
Key company profiles and industry landscape to provide latest market initiatives and competitive landscape
Impact of COVID`19 pandemic on ecosystem and the market
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services.
The Insight partners,